BACTANA CORP.
Postbiotic mixture from beneficial gut bacteria for oral treatment of prediabetes and type 2 diabetes
- Sector
- Biotech
- Headquarters
- FARMINGTON, CT
- Founded
- 2016
- Latest Form D
- $385K, Jul 2022
- Total capital
- $2.2M
- Federal grants
- $438K
- 2 awards · 2022
- Rank in peer group#180 of 392
- Private capital raised
- $1.8M
- 3 Form D · last Jul 2022
- 52 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 3 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$385K
- Federal grantAgriculture · There Is A Pressing Need To Increase Animal Numbers, Animal Productivity, And Ultimately Animal Protein Production Without Intensifying The Environmental Footprint Of Agriculture, Promoting Antibiotic Resistance, And Increasing Costs To The Producer. The Use Of Probiotics And Their Extracts Are Increasing As The Understanding Of The Role Of The Microbiome In Various Physiological Processes Increases. This Phase I Proposal Is Directed At Developing And Demonstrating The Feasibility Of Using A Mix$182K
- Federal grantNSF · Phase I · SBIR Phase I: Faecalibacterium prausnitzii supernatant oral formulations to improve insulin sensitivity and treat prediabetes$256K
- Private capital raisedForm D · SEC · 2nd filing$25K
- Private capital raisedForm D · SEC · 1st filing$1.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#180 · top 46%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Chen WangDirectorNamed in SEC Form D filings
- David WurzerDirectorNamed in SEC Form D filings
- John KallassyExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Peter LongoDirectorNamed in SEC Form D filings
- Randolph SeidlerDirectorNamed in SEC Form D filings
- Rodrigo BicalhoExecutive Officer, Director, PromoterNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 3- PendingMethods And Compositions For Treating Metabolic ConditionsUSPTOApplication PCTUS2021043971
- PendingMethods And Compositions For Improving Food Safety And Enhancing Feed Efficiency In PoultryUSPTOApplication 63152806
- PendingMethods And Compositions For Treating Metabolic ConditionsUSPTOApplication 63059130
Related companies, and why
- Medium CorpSimilar federal contract value in Biotech · null in contracts
- Serotiny, Inc.Similar federal contract value in Biotech · null in contracts
- Berkeley Fermentation Science Inc.Similar federal contract value in Biotech · null in contracts
- NOVOME BIOTECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
- Ichor Biologics LLCSimilar federal contract value in Biotech · null in contracts
- CryptoMedix, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .